A novel antagonist of the prostaglandin E₂ EP₄ receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models

PGE(2) stimulates EP(4) receptors to promote Th1 differentiation and Th17 expansion and is critically involved in development of arthritis in two animal models. Selective suppression of EP(4) receptor signalling may have therapeutic value in RA both by modifying inflammatory arthritis and by relieving pain.